hepatic hemangioma
Conditions
Interventions
Microwave ablation group:No
Sponsors
Beijing Chao-Yang Hospital, Capital Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age = 18 years; 2. Diagnosis of hepatic hemangioma confirmed by contrast-enhanced MRI and/or contrast-enhanced CT; 3. Meeting the indications for hepatic hemangioma treatment; 4. Fulfilling the definition of "high-surgical-risk" (meeting at least one of the following criteria): (1) Type I: The tumor is located in the middle lobe or caudate lobe of the liver and adjacent to important vascular structures of the first or second hepatic hilum. The definition of "adjacent to important hepatic vascular structures" is as follows: the distance between the hepatic hemangioma and the primary branches of the portal vein, hepatic vein, or inferior vena cava is = 1 cm; (2) Type II: Insufficient future liver remnant (FLR) anticipated after resection of single or multiple hemangiomas. FLR = (total liver volume - resected liver volume - tumor volume) / total liver volume × 100%. For patients with normal liver function and no underlying liver disease, FLR < 30%; for those with chronic liver disease, liver parenchymal damage, or cirrhosis, FLR < 40% is defined as insufficient residual liver; 5. Regular follow-up records within one year after surgery (completing follow-up examinations at 1, 6, and 12 months postoperatively); 6. Signed informed consent and agreement to participate in this study.
Exclusion criteria
Exclusion criteria: 1. Severe impairment of major organs, such as the heart, liver, lungs, or kidneys; 2. Presence of uncontrolled systemic infection, severe coagulation dysfunction (refractory to standardized correction), and/or malignancy; 3. Incomplete or missing clinical and follow-up data, precluding effective analysis; 4. Microwave ablation was performed as part of a combined treatment approach concurrently with surgical resection or hepatic artery embolization, making it impossible to assess the ablation effect independently.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| complication;radiologic response rate;clinical response rate;technical success rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| ablation time; intraoperative bleeding;postoperative hospital stay;complete ablation rate; | — |
Countries
China
Contacts
Public ContactGao Jun
Beijing Chao-Yang Hospital, Capital Medical University
Outcome results
None listed